ArticleProceedings of the National Academy of Sciences of the United States of America1995
The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 230 citations in OpenAlex.
- Krüppel-like factor 12 decreases progestin sensitivity in endometrial cancer by inhibiting the progesterone receptor signaling pathway.Translational oncology · 2024Article
- Crucial role of the transcription factors family activator protein 2 in cancer: current clue and views.Journal of translational medicine · 2023Review
- AP-2α Regulates S-Phase and Is a Marker for Sensitivity to PI3K Inhibitor Buparlisib in Colon Cancer.Molecular cancer research : MCR · 2021Article
- Fragile GeneFrontiers in oncology · 2021Article
- Pim1 Kinase Inhibitors Exert Anti-Cancer Activity Against HER2-Positive Breast Cancer Cells Through Downregulation of HER2.Frontiers in pharmacology · 2021Article
- AMolecular cancer research : MCR · 2020Article
- IgG based immunome analyses of breast cancer patients reveal underlying signaling pathways.Oncotarget · 2019Article
- The miR-26a/AP-2α/Nanog signaling axis mediates stem cell self-renewal and temozolomide resistance in glioma.Theranostics · 2019Article
- The atypical mitogen-activated protein kinase ERK3 is essential for establishment of epithelial architecture.The Journal of biological chemistry · 2018Article
- Transcriptional Regulation and Genes Involved in First Lineage Specification During Preimplantation Development.Advances in anatomy, embryology, and cell biology · 2018Article
- Nucleophosmin/B23 is a negative regulator of estrogen receptor α expression via AP2γ in endometrial cancer cells.Oncotarget · 2016Article
- CCR2-V64I genetic polymorphism: a possible involvement in HER2+ breast cancer.Clinical and experimental medicine · 2016Review
- Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance.Cell · 2016Article
- TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis.Oncogene · 2015Article
- Association of the human astrocyte elevated gene-1 promoter variants with susceptibility to hepatocellular carcinoma.Medical oncology (Northwood, London, England) · 2014Article
- Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies.Oncogene · 2014Article
- Ectopic expression of AP-2α transcription factor suppresses glioma progression.International journal of clinical and experimental pathology · 2014Article
- Chromatin modifications sequentially enhance ErbB2 expression in ErbB2-positive breast cancers.Cell reports · 2013Article
- Mutations in lipopolysaccharide-binding protein (LBP) gene change the susceptibility to clinical mastitis in Chinese Holstein.Molecular biology reports · 2012Article
- Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer.Neoplasia (New York, N.Y.) · 2012Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overexpression of the c-erbB-2/HER2 protooncogene in breast carcinoma is controlled not only by the degree of amplification of the gene but also at the level of gene transcription. Thus, whether or not the gene is amplified, the activity of the c-erbB-2 promoter is enhanced in overexpressing cells through the binding of an additional transcription factor, OB2-1, whose activity is increased in these lines. Here we describe further characterization of OB2-1 and show that it is identical to the developmentally regulated transcription factor AP-2. Functional assays confirm that AP-2 is able to regulate c-erbB-2 expression in mammary-derived cell lines. Furthermore, although AP-2 is barely detectable in cells with the low c-erbB-2 expression phenotype, protein levels are clearly elevated in a panel of c-erbB-2-overexpressing lines. These findings demonstrate an important role for this transcription factor in human cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.